Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals: The Cremona Study by Calori, Giliola et al.
Prevalence, Metabolic Features, and
Prognosis of Metabolically Healthy Obese
Italian Individuals
The Cremona Study
GILIOLA CALORI, MD
1
GUIDO LATTUADA, PHD
1,2
LORENZO PIEMONTI, MD
3
MARIA PAOLA GARANCINI, MD
4
FRANCESCA RAGOGNA, PHD
1
MARCO VILLA, MD
5
SALVATORE MANNINO, MD
5
PAOLO CROSIGNANI, MD
6
EMANUELE BOSI, MD
1
LIVIO LUZI, MD
1,2
GIACOMO RUOTOLO, MD
1,7
GIANLUCA PERSEGHIN, MD
1,2
OBJECTIVE — Some obese individuals have normal insulin sensitivity. It is controversial
whether this phenotype is associated with increased all-cause mortality risk.
RESEARCH DESIGN AND METHODS — Fifteen-year all-cause mortality data were
obtained through the Regional Health Registry for 2,011 of 2,074 Caucasian middle-aged indi-
viduals of the Cremona Study, a population study on the prevalence of diabetes in Italy. Indi-
viduals were divided in four categories according to BMI (nonobese: 30 kg/m
2; obese: 30
kg/m
2) and estimated insulin resistance (insulin sensitive: homeostasis model assessment of
insulin resistance 2.5; insulin resistant 2.5).
RESULTS — Obese insulin-sensitive subjects represented 11% (95% CI 8.1–14.5) of the
obese population. This phenotype had similar BMI but lower waist circumference, blood pres-
sure, fasting glucose, triglycerides, and ﬁbrinogen and higher HDL cholesterol than obese insu-
lin-resistant subjects. In the 15-year follow-up, 495 deaths (cardiovascular disease [CVD]: n 
221; cancer: n  180) occurred. All-cause mortality adjusted for age and sex was higher in the
obese insulin-resistant subjects (hazard ratio 1.40 [95% CI 1.08–1.81], P 0.01) but not in the
obese insulin-sensitive subjects (0.99 [0.46–2.11], P  0.97) when compared with nonobese
insulin-sensitive subjects. Also, mortality for CVD and cancer was higher in the obese insulin-
resistant subjects but not in the obese insulin-sensitive subjects when compared with nonobese
insulin-sensitive subjects.
CONCLUSIONS — In contrast to obese insulin-resistant subjects, metabolically healthy
obeseindividualsarelesscommonthanpreviouslythoughtanddonotshowincreasedall-cause,
cancer, and CVD mortality risks in a 15-year follow-up study.
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M
etabolically healthy obese (MHO)
individuals are considered as a
subset of obese subjects without
metabolic abnormalities (such as insulin
resistance, proatherogenic lipoprotein
proﬁle, proinﬂammatory state, or hyper-
tension) and a model for better under-
standing the pathogenesis of insulin
resistance (1–3). The prevalence of the
MHO phenotype in the general popula-
tion, the reasons for not developing met-
abolic alterations, and the less aggressive
therapeutic approach with respect to
obese individuals with metabolic abnor-
malities are currently debated (4,5). In
the Framingham Offspring Study, Meigs
et al. (6) found that MHO individuals do
not have increased risk of incident diabe-
tes and cardiovascular disease (CVD).
Conversely, in the Third National Health
and Nutrition Examination Survey
(NHANES III), Kuk et al. (7) reported in-
creased all-cause mortality associated
with the MHO phenotype. Finally, in a
Scandinavian study (8), middle-aged
overweight/obese subjects without meta-
bolicsyndromealsohadanincreasedrisk
of CVD when compared with normal-
weight individuals without metabolic
syndrome. The present study shows the
prevalence of the MHO phenotype, its
metabolic features, and 15-year all-cause,
CVD, and cancer mortality rates in the
Caucasian population of the Cremona
Study (9,10).
RESEARCH DESIGN AND
METHODS
Study cohort and follow-up
The Cremona Study is a population sur-
vey carried out in 1990–1991 in the
health district of Cremona (Lombardia,
Italy) to determine the prevalence of dia-
betes according to the oral glucose toler-
ance test (OGTT) and World Health
Organization criteria (8,9). A total of
2,074 individuals were enrolled. Past
medical history, anthropometric mea-
sures, and clinical data of subjects were
collected by trained interviewers using
standardizedprocedures.Avenousblood
sample was collected after a 12-h over-
night fast, and thereafter a 75-g oral glu-
cose monohydrate was given. An
additionalbloodsamplewascollected2h
later. Heart rate and blood pressure were
recorded twice, at the beginning and at
the end of the visit, in the sitting position,
and after at least 10 min rest using a full
automatic noninvasive sphyngomanom-
eter. The lowest ﬁgure was considered.
Further details concerning the study pro-
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tal status and time of death were acquired
from the Regional Health Registry (up-
dated to 31 December 2005), and causes
of death were classiﬁed using the ICD-9
(deathcodesforCVDarefrom401to448
and cancer from 140.0 to 208.9). Median
follow-up was 180 months, and median
follow-up of those still alive at 182
months(98%ofthosewhowerestillalive
had a minimum follow-up period of 174
months).Datafor2,011of2,074individ-
uals were available.
Deﬁnition of study groups
Study subjects were divided in four cate-
gories based on BMI (nonobese: 30 kg/
m
2; obese: 30 kg/m
2) and estimated
insulin resistance (insulin sensitive: ho-
meostasis model assessment of insulin re-
sistance [HOMA-IR] 2.5; insulin
resistant 2.5). The cutoff of 2.5 for
HOMA-IR was chosen to compare our
data with those recently published by
Kuk et al. (7). Therefore, the four catego-
ries were 1) the nonobese subjects with
normal insulin sensitivity, 2) the obese
but insulin-sensitive subjects, 3) the
nonobese but insulin-resistant subjects,
and 4) the obese and insulin-resistant
subjects. The features of these subgroups
are summarized in Table 1.
Deﬁnition of diabetes, impaired
glucose tolerance, and metabolic
syndrome
Diabeteswasdeﬁnedaccordingtotheuse
of oral hypoglycemic agents or insulin
and according to the World Health Orga-
nization diagnostic criteria for the OGTT
(basal plasma glucose 7.8 mmol/l or
11.1 mmol/l after a 2-h oral glucose
load). Patients with manifest diabetes did
notundergotheOGTT.Impairedglucose
tolerancewasdeﬁnedasbasalplasmaglu-
cose 7.8 mmol/l and plasma glucose
7.8but11mmol/laftera2-horalglu-
cose load. Metabolic syndrome was de-
ﬁned accordingly to the deﬁnition of the
National Cholesterol Education Program
Adult Treatment Program III.
Analytical determinations
Blood, serum, and plasma measurements
were done as previously described (8,9).
Calculations
BMIwascalculatedasweightinkilograms
divided by the square of height in meters
and alcohol consumption as grams of al-
cohol (glass of wine  20 g, glass of aper-
itif  30 g, and glass of liquor  80 g).
HOMA-IR was calculated as previously
described (11), and LDL cholesterol was
calculated using the Friedwald formula.
Statistical analysis
DataarepresentedasmeansSD,unless
otherwise indicated. Serum insulin, trig-
lycerides, ﬁbrinogen, and glucose had a
skewed distribution; therefore, log-
transformed values were used in the anal-
ysis.ANOVAandTukeyposthocanalysis
were used for comparison between
Table 1—Baseline anthropometric, clinical, and laboratory features of study groups
Nonobese
insulin-sensitive
subjects
Obese
insulin-sensitive
subjects
Nonobese
insulin-resistant
subjects
Obese
insulin-resistant
subjects
Anthropometric parameters
n (female/male) 708 (392/316) 43 (31/12) 923 (512/411) 337 (191/146)
Age (years) 55  11*† 55  95 9  11‡§ 59  10‡§
BMI (kg/m
2) 23.8  2.8*†§ 32.5  4.3†‡ 25.8  2.3*‡§ 33.3  3.4†‡
Waist circumference (cm) 82  9*†§ 94  4*†‡ 89  10*‡§ 104  11†‡§
Actual smoking 201 (28%)¶ 8 (19%) 177 (19%) 64 (19%)
Alcohol intake (g/day) 44  59 39  45 42  59 39  54
Systolic blood pressure (mmHg) 139  20*† 143  23* 147  21*‡ 154  20†‡§
Diastolic blood pressure (mmHg) 77  11*† 79  13* 81  12*‡ 85  12†‡§
Heart rate (beats/min) 73  11*† 72  10 76  13‡ 77  11‡
Biochemical lab parameters
Glucose (mmol/l) 4.83  0.50*† 4.83  0.33*† 5.44  1.05†‡§ 6.00  1.67†‡§
Cholesterol (mmol/l) 5.92  1.09† 6.20  1.19 6.20  1.14‡ 6.10  1.14
HDL cholesterol (mmol/l) 1.52  0.36*† 1.50  0.34*† 1.29  0.36 *‡§ 1.21  0.34†‡§
LDL cholesterol (mmol/l) 3.90  1.03*† 4.13  1.00 4.19  1.03‡ 4.11  1.06‡
Triglycerides (mmol/l) 1.15  0.63*† 1.26  0.58*† 1.56  1.04*‡ 1.72  0.94†‡§
Alanine aminotransferase (units/l) 21  14*† 23  12* 27  22*‡ 31  26†‡§
Aspartate aminotransferase (units/l) 26  12* 25  82 8  13 30  19‡
GT (units/l) 31  38*† 33  41 42  58‡ 50  82‡
ALP (units/l) 169  64*† 159  52* 180  66‡ 187  76‡§
Fibrinogen (mg/dl) 271  66*† 274  48*† 286  74*‡ 302  76‡§
Hormones
Insulin (pmol/l) 50  13*† 56  13*† 112  70*‡§ 154  89†‡§
Insulin sensitivity, metabolic syndrome, diabetes status
HOMA-IR 1.80  0.45*† 2.00  0.43*† 4.65  3.70*‡§ 7.18  5.57†‡§
Metabolic syndrome 37 (5%) 3 (7%) 218 (24%)  139 (41%) 
Diabetes 16 (2%) 0 (0%) 98 (11%)  74 (28%) 
Data are means  SD or n (%), unless otherwise indicated. One-way ANOVA and Tukey post hoc for continuous variables. *P  0.05 vs. obese insulin-resistant
subjects; †P  0.05 vs. nonobese insulin-resistant subjects; ‡P  0.05 vs. nonobese insulin-sensitive subjects; §P  0.05 vs. obese insulin-sensitive subjects. 
2 for
categorical variables ¶P  0.05 vs. all;  P  0.05 vs. nonobese and obese insulin-sensitive subjects.
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tween groups were tested by the 
2 test.
The associations of each investigated risk
factor with all-cause, CVD, and cancer
mortality were estimated by the Cox pro-
portional hazard model, with adjust-
ments for age and sex. Multivariate Cox
regression analysis was performed to ad-
just the comparisons of mortality among
the different subgroups for possible con-
foundingfactors.Hazardratios(HRs)and
95% CIs are presented. Proportions’ 95%
CIs were calculated using the normal ap-
proximation or the exact method. Kaplan
and Meier curves for all-cause mortality
were plotted for the four groups, as pre-
viously described. A P value 0.05 indi-
cated statistical signiﬁcance. Analyses
were performed using SAS software (ver-
sion 9.1).
RESULTS
Prevalence of the obese insulin-
sensitive phenotype
Of 2,011 subjects, 708 were nonobese
and insulin sensitive, 923 nonobese and
insulin resistant, and 337 obese and insu-
lin resistant. There were a total of 43
obeseinsulin-sensitiveindividuals,repre-
senting 11.0% (95% CI 8.1–14.5) of the
obese population and 2.1% (1.6–2.9) of
the entire population.
Anthropometric and metabolic
features of obese insulin-sensitive
individuals
The features of the four groups are sum-
marized in Table 1. Sex distribution did
not differ among all groups, whereas cig-
arette smoking was more frequent in
nonobese insulin-sensitive subjects than
all other groups. Systolic and diastolic
blood pressure, heart rate, plasma glu-
cose, insulin, total cholesterol, HDL cho-
lesterol, triglycerides, transaminases,
-glutamyltransferase (GT), alkaline
phosphatase (ALP), and ﬁbrinogen did
not differ between the two insulin-
sensitive groups.
Individuals in the insulin-sensitive
groups were younger, had lower heart
rates,hadhigherplasmaHDLcholesterol,
and had lower ﬁbrinogen and triglycer-
ides, as well as had a lower prevalence of
diabetesandmetabolicsyndromethanin-
sulin-resistant groups. Waist circumfer-
encewashigherinobeseinsulin-sensitive
than nonobese insulin-resistant subjects
but were lower than in obese insulin-
resistant subjects. Systolic and diastolic
blood pressure, plasma transaminases,
GT, and ALP were higher in the two
groups of insulin-resistant subjects than
in nonobese insulin-sensitive subjects.
Mortality in the cohort
During the 15-year observation period,
495 deaths occurred. A total of 221
deaths were CVD related and 180 were
cancer related. Age and sex were associ-
ated with higher all-cause mortality (age:
HR 1.11 [95% CI 1.10–1.12], P 
0.0001; female sex: 0.42 [0.35–0.50],
P0.0001),mortalityforCVD(age:1.15
[1.13–1.17], P  0.0001; female sex:
0.40[0.31–0.53],P0.0001),andmor-
tality for cancer (age: 1.07 [1.06–1.09],
P  0.0001; female sex: 0.39 [0.29–
0.52], P  0.0001). All-cause mortality
was higher in the obese insulin-resistant
subjects (31%) in comparison with the
reference group of nonobese insulin-
sensitive subjects (20%) (age- and sex-
adjustedHR1.4,P0.01)(Table2)(Fig.
1) but not in the obese insulin-sensitive
subjects (12%) (0.99,P0.97) (Table 2)
(Fig. 1) and in the nonobese insulin-
resistant subjects (26%) (1.11, P  0.35)
(Table 2) (Fig. 1).
Also, mortality for CVD (15%, P 
0.015)andcancer(12%,P0.04)(Table
2) was higher in the obese insulin-
resistant subjects but not in the obese in-
sulin-sensitivesubjects(CVDrelated:5%,
P  0.66, and cancer related: 7%, P 
0.95)andnonobeseinsulin-resistantsub-
jects (CVD related: 12%, P  0.29, and
cancer related: 9%, P  0.64) when com-
pared with nonobese insulin-sensitive
subjects (CVD related: 8% and cancer re-
lated: 7%).
Because the prevalence of cigarette
smokingandbaselineplasmaLDLcholes-
terolweredifferentamongthegroups,we
performed the analysis adjusting also for
these two factors. All-cause mortality re-
mained higher in the obese insulin-
resistantsubjects(HR1.66[95%CI1.12–
2.46], P  0.011) but not in obese
insulin-sensitive subjects (0.79 [0.19–
3.28],P0.75)andinnonobeseinsulin-
resistant subjects (1.22 [0.88–1.70], P 
0.23)whencomparedwithnonobeseand
insulin-sensitive subjects.
The analysis was also repeated after
the exclusion of diabetic patients. When
compared with nonobese insulin-
sensitive (reference group), all-cause
mortality tended to be higher in obese in-
sulin-resistantsubjects(HR1.29[95%CI
0.96–1.73],P0.087)butwasagainnot
different in obese insulin-sensitive sub-
jects (1.01 [0.47–2.17], P  0.97) and
nonobese insulin-resistant subjects (1.00
[0.80–1.25], P  0.98). Similarly, mor-
tality for CVD and cancer tended to be
higher in obese insulin-resistant subjects
(CVD: HR 1.40 [95% CI 0.94–2.11], P 
0.071; cancer: 1.46 [0.94–2.27], P 
0.097) but was not different in obese in-
sulin-sensitive subjects (CVD: 0.76
[0.197–3.11], P  0.71; cancer: 1.05
[0.33–3.56], P  0.94) and nonobese in-
sulin-resistant subjects (CVD: [1.09
[0.77–1.54], P  0.65; cancer: 1.01
[0.93–2.27],P0.95)thannonobesein-
sulin-sensitive subjects.
Finally, instead of the preselected
HOMA-IRof2.5,werepeatedtheanalysis
using cutoff values (top tertile and top
quartile) for HOMA-IR obtained from
the present study. Even in this case, the
results did not change (see the on-
Table 2—Cox proportional hazard model adjusting for age and sex
n events/n HR (95% CI) P
All-cause mortality
Nonobese insulin-sensitive subjects 141/708 — —
Obese insulin-sensitive subjects 7/43 0.99 (0.46–2.11) 0.97
Nonobese insulin-resistant subjects 241/923 1.11 (0.90–1.36) 0.35
Obese insulin-resistant subjects 106/337 1.40 (1.08–1.81) 0.01
CVD mortality
Nonobese insulin-sensitive subjects 58/708 — —
Obese insulin-sensitive subjects 2/43 0.73 (0.18–3.00) 0.66
Nonobese insulin-resistant subjects 112/923 1.19 (0.86–1.64) 0.29
Obese insulin-resistant subjects 49/337 1.61 (1.10–2.36) 0.015
Cancer mortality
Nonobese insulin-sensitive subjects 51/708 — —
Obese insulin-sensitive subjects 3/43 1.04 (0.32–3.30) 0.95
Nonobese insulin-resistant subjects 85/923 1.09 (0.78–1.52) 0.64
Obese insulin-resistant subjects 41/337 1.52 (1.02–2.26) 0.04
Prognosis of metabolically healthy obese subjects
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CONCLUSIONS — The 15-year fol-
low-up of the Cremona Study demon-
strates that obese insulin-sensitive
individuals, also known as MHO individ-
uals 1) have a prevalence of 11% in the
obese population and 2% in the entire
population; 2) have less features of the
metabolic syndrome, when compared
with obese insulin-resistant individuals;
and 3) do not have increased all-cause,
CVD, and cancer mortality, when com-
pared with nonobese insulin-sensitive
(reference group) subjects.
Major ﬁndings and comparison with
the literature
The prevalence of the obese insulin-
sensitive phenotype (11%) in our obese
cohort was lower than reported by Iaco-
bellis et al. (3) (27.5%) in a cohort of 681
obese individuals living in Rome and the
surrounding areas. The discrepancy may
be related to the different regional habits
oftheItaliancohortsbutmostlikelytothe
different deﬁnition of MHO. Iacobellis et
al. based their deﬁnition mainly on the
metabolicsyndrome;meanwhile,ourdef-
inition was centered on HOMA-IR, a sur-
rogateindexofinsulinresistance,inorder
tocompareourresultswiththoserecently
published by Kuk and Ardern (7), who
analyzed the NHANES III survey in U.S.
usingHOMA-IR2.5asthecutoff.Inter-
estingly, they reported a prevalence of
metabolicallyhealthysubjectsof6%.Our
ﬁnding is in line with this report (7);
therefore, we think that the frequency of
this phenotype is lower than previously
thought.
The present study has also clearly
shown that the obese insulin-sensitive
phenotype carries less features of the
metabolic syndrome. These subjects
were characterized by lower waist cir-
cumference, blood pressure, circulating
triglycerides, transaminases, GT (as a
surrogate markers of fatty liver), and ﬁ-
brinogen (as a surrogate marker of low-
grade inﬂammation), when compared
with the obese insulin-resistant subjects,
in spite of similar BMIs. Not surprisingly,
they had a lower prevalence of the meta-
bolic syndrome (7% in comparison to the
observed 41% in the obese insulin-
resistant subjects) and of diabetes (0 vs.
28% of the obese insulin-resistant sub-
jects). We think, therefore, that the dele-
terious metabolic features associated with
obesity are largely related to the presence
of insulin resistance rather than obesity,
per se.
Figure1—SurvivalbyKaplan-Meierestimatesofall-causemortality.Follow-upperiodwas15years(180months).Subjectsweredividedaccording
to BMI (nonobese: 30 kg/m
2; obese: 30 kg/m
2) and estimated insulin resistance (insulin sensitive: HOMA-IR 2.5; insulin resistant: 2.5). At
the bottom are the detailed ﬁgures of the number at risk for each subgroup of individuals. NOb-IR, nonobese insulin-resistant subjects; NOb-IS,
nonobese insulin-sensitive subjects (the reference); Ob-IR, obese insulin-resistant subjects; Ob-IS, obese insulin-sensitive subjects.
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prognosis of the MHO subjects. The
present study has also shown that all-
cause mortality is signiﬁcantly higher in
obese insulin-resistant subjects but not
obese insulin-sensitive subjects, when
compared with nonobese insulin-
sensitive individuals (considered as refer-
ence group). These ﬁndings were
conﬁrmedwhentheanalysiswasadjusted
forLDLcholesterolandcigarettesmoking
(risk factors not related to metabolic syn-
drome). However, our ﬁndings are in
contrastwithrecentdatafromaU.S.pop-
ulation that suggest increased all-cause
mortality in MHO subjects (deﬁned ac-
cording to the same BMI and HOMA-IR
criteria we use here) (7). The potential
explanations for this discrepancy are
number of events, reference HR, and dif-
ferent ethnicity. Even though our popu-
lation was smaller, the number of events
was higher (495 vs. 292, or 25 vs. 5%).
This was likely because of the longer ob-
servational period (15 vs. 8.7 years). It is
important to point out that a 10- to 15-
year follow-up may be the least to see the
effects of metabolic risk factors on mor-
tality(8,12).RegardingreferenceHRs,we
studied nonobese insulin-sensitive indi-
viduals, which also includes overweight
individuals with BMIs ranging between
25and29.9kg/m
2,whereasKuketal.(7)
studied normal-weight insulin-sensitive
subjects with BMI 25 kg/m
2.
Our ﬁnding is also in contrast with
another report by Arnlov et al. (8) in a
Scandinavianpopulationinwhichover-
weight and obese individuals without
the metabolic syndrome showed a
higher mortality when compared with
normal-weight and insulin-sensitive in-
dividuals.Webelievethatthereasonfor
this discrepancy could be attributed to
sex differences because our study in-
cluded both male and female subjects,
whereas only male subjects were in-
cluded in the Scandinavian study. This
is worth mentioning because male sex
was a signiﬁcant risk factor for all-cause
mortality in our study.
We used all-cause mortality as pri-
mary outcome (because this variable is
less affected by errors in reporting),
whereas CVD and cancer mortality were
considered secondary outcomes. Mortal-
ity for CVD and cancer, as for all-cause
mortality, were also higher in obese insu-
lin-resistant individuals but not in the
MHO subjects.
Strengths and limitations
The following are major strengths of the
present study: 1) this was a population-
based study including both male and fe-
male subjects, 2) there was careful and
homogeneous acquisition of the anthro-
pometric parameter of interest, 3) there
was a robust end point (all-cause mortal-
ity) whose ascertainment was based on
the Regional Health Registry, and 4) there
was a long follow-up period (15 years).
The following are the limitations of
this study: 1) there was a small sample
sizeofthegroupofobeseinsulin-sensitive
subjects (n  43), and their low preva-
lenceinthecohort(2%)couldrepresenta
problem because of the consequent small
number of events even if it was similar to
previously reported data (8); 2) there was
a lack of collection of intermediate data
points about the parameters of interest
during the 15-year observation period; 3)
the glucose clamp technique is the gold
standard for the assessment of insulin
sensitivity and HOMA is inferior; never-
theless, it was suggested that HOMA ap-
peared to be speciﬁcally suited to large-
scale epidemiologic studies in which only
fasting glucose and insulin concentra-
tionswereavailable(13);and4)therewas
a lack of collection of the dietary habits
and habitual physical activity, known to
have a well recognized impact on insulin
sensitivity.
Pathogenic remarks
It is currently unclear why these MHO
subjectsmaybeprotected.Itwasreported
thataloweramountofvisceralfatcontent
maycontributetothefavorablemetabolic
proﬁle (1,6). Fitting this view, the waist
circumference was lower in MHO sub-
jects than in the obese insulin-resistant
subjects; on the other hand, it was higher
in comparison to the nonobese and insu-
lin-sensitive group (Table 1), in spite of a
similar all-cause mortality. We speculate
that visceral fat and insulin resistance
may, in combination, explain the differ-
ence and the trends observed between
groups in our study, and, in addition, an
undetectable effect of ectopic fat accumu-
lation in the skeletal muscle (14) and the
liver(15)shouldbeconsidered.Inpartic-
ular, the potential, but yet-to-be-
demonstrated, role of the liver (see the
proﬁle of surrogate markers of fatty liver)
in mediating the increased CVD mortality
may be hypothesized based on the proin-
ﬂammatory and proatherosclerotic pro-
ﬁle of individuals with nonalcoholic fatty
liverdiseasebutalsobasedonsomeinitial
epidemiological data (16).
All-cause mortality in obese insulin-
resistant subjects but not in MHO sub-
jects is higher when compared with
nonobese insulin-sensitive subjects. The
effect of obesity on the increasing risk is
strongly related with insulin resistance,
and we therefore agree with Bonora et al.
(17) and McLaughlin et al. (18) that it is
important to not limit our risk evaluation
totheidentiﬁcationofobesityalonebutto
put more effort into identifying those at
higher risk, insulin-resistant obese
individuals.
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